Patent ID: 8211898

Claim:
A method of inhibiting a human immunodeficiency virus (HIV) comprising contacting said immunodeficiency virus with a compound of formula I: wherein the dashed line represents a double bond located between A and C(V); A is C(Z); D is S; T is NH, O, or S; Z is H, F, Cl, Br, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, OC 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, OC 3 -C 6 cycloalkyl, phenyl or benzyl; wherein the alkyl, alkenyl, cycloalkyl, phenyl groups and the phenyl moiety of the benzyl group are optionally substituted with 1-3 groups selected from halogen, CF 3 , C 1 -C 3 alkyl, or OC 1 -C 3 alkyl; V is H, halogen, C 1 -C 6 alkyl; Ar is selected from (a), (b), (c), or (d) below: wherein each R P is selected from methyl, ethyl, propyl, isopropyl, cyclopropylmethyl, C 3 -C 6 cycloalkyl, cyano, CH═CHCN, Cl, Br, I, acetyl, or C 1 -C 6 alkyl-NH; R 4 , R 5 , and each R 6 are independently selected from H, F, Cl, Br, CH 3 , CF 3 , CH 2 F, CHF 2 , isopropyl, cyclopropyl, OCH 3 , OH, OCF 3 , NH 2 or NHCH 3 ; or R 6 and R P on adjacent ring atoms, together with the ring atoms to which they are attached, form an additional fused five-membered ring; Q and Q are independently selected from N or CH; R 7 is Cl, Br, I, CH 3 , CF 3 , OCH 3 , isopropyl, cyclopropyl, t-butyl, or cyclobutyl; and R 8 , R 9 , R 10 and —R 11 are, independently, H or CH 3 ; or a pharmaceutically acceptable salt thereof.